Monopar Therapeutics Inc ((MNPR)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Monopar Therapeutics Inc. is conducting an open-label pilot study titled Open Label Pilot Study Evaluating Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors. The study aims to assess the effectiveness of a new PET/CT imaging agent, MNPR-101-DFO*-89Zr, in detecting solid tumors, including bladder, breast, lung, and other cancers. This research is significant as it could improve diagnostic accuracy and potentially guide therapy decisions in the future.
The intervention involves a single infusion of the drug MNPR-101-DFO*-89Zr, a combination of a monoclonal antibody and a radioisotope, followed by PET/CT imaging to identify tumor locations. This innovative approach could enhance tumor detection and treatment planning.
The study is interventional with a sequential model and no masking, focusing primarily on diagnostics. Participants receive a single drug infusion, followed by three PET/CT scans over ten days to evaluate the imaging agent’s efficacy.
Key dates for the study include a start date of March 22, 2024, with the latest update on May 19, 2025. These dates are crucial for tracking the study’s progress and any potential impacts on the market.
The study’s progress could influence Monopar Therapeutics’ stock performance by demonstrating innovation in cancer diagnostics, potentially attracting investor interest. This development is noteworthy in the competitive oncology diagnostics market, where advancements can significantly impact company valuations.
The study is ongoing, and further details are available on the ClinicalTrials portal.